Business
NRx Pharmaceuticals to Report First Quarter 2022 Results on May 16, 2022
--Company to Host Conference Call May 16, 2022, at 8:30AM ET-- RADNOR, Pa., May 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"--Company to Host Conference Call May 16, 2022, at 8:30AM ET--\nRADNOR, Pa., May 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\"), a clinical-stage, biopharmaceutical company today announced that management will report first quarter 2022 financial results prior to the market open on May 16, 2022. The company will host a conference call and webcast on May 16, 2022, 8:30AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period. Investors interested in submitting questions must do so in advance of the call and are encouraged to email questions to the Company's investor relations representative at [email protected] by 4:00 PM Eastern Time on May 13, 2022.\n\n \n \n \n \n \n \n\n \nThe company will host a conference call/webcast 5/16/22, @8:30 AM ET to discuss results and provide a corporate update.Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing (877) 407-9716 (U.S.), (201) 493-6779 (International) Conference ID: 13729829, or through the webcast link NRx Pharmaceuticals First Quarter 2022 Earnings Call. A replay will be available from the NRx Pharmaceuticals website following the call at www.nrxpharma.com.\nAbout NRx Pharmaceuticals\nNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\" or the \"Company\") draws upon decades of collective, scientific, and drug-development experience to bring improved health to patients. Its investigational product, ZYESAMI® (aviptadil) for patients with COVID-19, has been granted Fast Track designation by the US Food and Drug Administration (FDA) and is in a Phase III trial for Critical COVID-19 patients which is sponsored and managed by the US National Institutes of Health. The FDA has additionally granted Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101, an investigational medicine for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB) after initial stabilization with ketamine or other effective therapy.\nNRx Pharmaceuticals is led by executives and board members who have held senior roles at Lilly, ...